Halozyme Therapeutics Signs Collaboration, License Deal With Vertex Pharmaceuticals For Hypercon
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with


































